Evidence
Nutrients. 2023 Apr 25;15(9):2068. doi: 10.3390/nu15092068.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by lipid accumulation in hepatocytes with low alcohol consumption. The development of sterile inflammation, which occurs in response to a range of cellular stressors or injuries, has been identified as a major contributor to the pathogenesis of NAFLD. Recent studies of the pathogenesis of NAFLD reported the newly developed roles of damage-associated molecular patterns (DAMPs). These molecules activate pattern recognition receptors (PRRs), which are placed in the infiltrated neutrophils, dendritic cells, monocytes, or Kupffer cells. DAMPs cause the activation of PRRs, which triggers a number of immunological responses, including the generation of cytokines that promote inflammation and the localization of immune cells to the site of the damage. This review provides a comprehensive overview of the impact of DAMPs and PRRs on the development of NAFLD.
PMID:37432213 | DOI:10.3390/nu15092068
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
🌐 90 Days
VR Related Evidence Matrix
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Innate immune activation in neurodegenerative diseases
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Bacteroides and NAFLD: pathophysiology and therapy
- Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort
- Interleukins in liver disease treatment
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The Sixth Sense: Self-nucleic acid sensing in the brain
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
- Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Emerging roles of RNA-binding proteins in fatty liver disease
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
- Expression and localization of HSD17B13 along mouse urinary tract
- Expression and localization of HSD17B13 along mouse urinary tract
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Synthesis and biological evaluation of the novel chrysin prodrug for non-alcoholic fatty liver disease treatment
- The gut-liver axis in fatty liver disease: role played by natural products
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Unveiling the mitophagy puzzle in non-alcoholic fatty liver disease (NAFLD): Six hub genes for early diagnosis and immune modulatory roles
- A novel bellidifolin intervention mitigates nonalcoholic fatty liver disease-like changes induced by bisphenol F
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- The double roles of T cell-mediated immune response in the progression of MASLD
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies
- Concomitant NAFLD facilitates liver metastases and PD-1-refractory by recruiting MDSCs via CXCL5/CXCR2 in colorectal cancer
- Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation
- Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes
Evidence Blueprint
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
🌐 365 Days
VR Related Evidence Matrix
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Major roles of kupffer cells and macrophages in NAFLD development
- Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg
- Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Innate immune activation in neurodegenerative diseases
- Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis
- Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Macrophages and the development and progression of non-alcoholic fatty liver disease
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Histological features of non-alcoholic fatty liver disease revealed in response to mixed vehicle emission exposure and consumption of a high-fat diet in wildtype C57Bl/6 male mice
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- Cholesterol Exacerbates the Pathophysiology of Non-Alcoholic Steatohepatitis by Upregulating Hypoxia-Inducible Factor 1 and Modulating Microcirculatory Dysfunction
- C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Doxorubicin Attenuates Free Fatty Acid-Induced Lipid Accumulation via Stimulation of p53 in HepG2 Cells
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation
- Blood-brain crosstalk: the roles of neutrophils, platelets, and neutrophil extracellular traps in neuropathologies
- Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease
- Targeting Extracellular RNA Mitigates Hepatic Lipotoxicity and Liver Injury in NASH
- Bempedoic acid unveils therapeutic potential in non-alcoholic fatty liver disease: suppression of the hepatic PXR-SLC13A5/ACLY signaling axis
- Peripheral and central macrophages in obesity
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- High-cholesterol diet in combination with hydroxypropyl-beta-cyclodextrin induces NASH-like disorders in the liver of rats
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Insights of mitochondrial involvement in alcoholic fatty liver disease
- HMGA2 knockdown alleviates the progression of nonalcoholic fatty liver disease (NAFLD) by downregulating SNAI2 expression
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Effects of riboflavin deficiency and high dietary fat on hepatic lipid accumulation: a synergetic action in the development of non-alcoholic fatty liver disease
- Bacteroides and NAFLD: pathophysiology and therapy
- Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease
- Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- The Association between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III